Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ResMed Yönetim

Yönetim kriter kontrolleri 3/4

ResMed's CEO'su Mick Farrell, Mar2013 tarihinde atandı, in görev süresi 11.58 yıldır. in toplam yıllık tazminatı $ 13.87M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.1% maaş ve 91.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.32% ine doğrudan sahiptir ve bu hisseler € 103.27M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.7 yıl ve 8.9 yıldır.

Anahtar bilgiler

Mick Farrell

İcra Kurulu Başkanı

US$14.1m

Toplam tazminat

CEO maaş yüzdesi	8.3%
CEO görev süresi	11.6yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	2.7yrs
Yönetim Kurulu ortalama görev süresi	6.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Mick Farrell'un ücretlendirmesi ResMed'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	US$14m	US$1m	US$1b
Mar 31 2024	n/a	n/a	US$958m
Dec 31 2023	n/a	n/a	US$890m
Sep 30 2023	n/a	n/a	US$907m
Jun 30 2023	US$14m	US$1m	US$898m
Mar 31 2023	n/a	n/a	US$863m
Dec 31 2022	n/a	n/a	US$809m
Sep 30 2022	n/a	n/a	US$786m
Jun 30 2022	US$12m	US$1m	US$779m
Mar 31 2022	n/a	n/a	US$779m
Dec 31 2021	n/a	n/a	US$522m
Sep 30 2021	n/a	n/a	US$500m
Jun 30 2021	US$10m	US$1m	US$475m
Mar 31 2021	n/a	n/a	US$457m
Dec 31 2020	n/a	n/a	US$699m
Sep 30 2020	n/a	n/a	US$680m
Jun 30 2020	US$10m	US$1m	US$622m
Mar 31 2020	n/a	n/a	US$513m
Dec 31 2019	n/a	n/a	US$455m
Sep 30 2019	n/a	n/a	US$419m
Jun 30 2019	US$10m	US$967k	US$405m
Mar 31 2019	n/a	n/a	US$446m
Dec 31 2018	n/a	n/a	US$450m
Sep 30 2018	n/a	n/a	US$335m
Jun 30 2018	US$9m	US$934k	US$316m

Tazminat ve Piyasa: Mick 'nin toplam tazminatı ($USD 13.87M ), Austrian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.44M ).

Tazminat ve Kazançlar: Mick 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Mick Farrell (52 yo)

11.6yrs

Görev süresi

US$14,120,829

Tazminat

Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Farrell	CEO & Chairman	11.6yrs	US$14.12m	0.32% € 103.4m
Peter Farrell	Founder	no data	US$719.69k	0.057% € 18.4m
Brett Sandercock	Chief Financial Officer	18.8yrs	US$3.23m	0.065% € 21.2m
Michael Rider	Chief Legal Officer & Secretary	1.3yrs	US$2.15m	0.0015% € 496.1k
Justin Leong	Chief Product Officer	8.4yrs	US$3.60m	0.013% € 4.1m
Kaushik Ghoshal	Chief Commercial Officer - SaaS	2.7yrs	US$3.53m	0.015% € 4.8m
Alastair Robertson	Chief Information Officer	less than a year	Veri yok	Veri yok
Amy Wakeham	Chief Investor Relations Officer	1.5yrs	Veri yok	Veri yok
Jim Ellis	Chief Compliance Officer	6.8yrs	Veri yok	Veri yok
Yvonne-Katrin Pucknat	Chief Marketing Officer	less than a year	Veri yok	Veri yok
Vered Keisar	Chief People Officer	3.6yrs	Veri yok	Veri yok
Robert Douglas	Special Advisor	less than a year	US$6.67m	0% € 0

2.7yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: RMD 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Farrell	CEO & Chairman	11.6yrs	US$14.12m	0.32% € 103.4m
Peter Farrell	Founder	35.3yrs	US$719.69k	0.057% € 18.4m
Richard Sulpizio	Independent Director	19.2yrs	US$348.72k	0.010% € 3.3m
Ronald Taylor	Lead Independent Director	19.8yrs	US$381.22k	0.014% € 4.6m
Jan De Witte	Independent Non-Executive Director	5.4yrs	US$329.97k	0.0039% € 1.3m
Harjit Gill	Independent Director	5.9yrs	US$329.97k	0.0049% € 1.6m
Carol Burt	Independent Director	10.9yrs	US$369.97k	0.010% € 3.3m
Karen Drexler	Independent Director	6.9yrs	US$334.97k	0.0052% € 1.7m
Christopher DelOrefice	Independent Director	less than a year	Veri yok	Veri yok
Desney Tan	Independent Director	2.9yrs	US$329.97k	0.0014% € 460.4k
John Hernandez	Independent Director	2.9yrs	US$329.97k	0.0014% € 460.4k

6.9yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RMD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.9 yıldır).

ResMed Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

ResMed Inc., Annual General Meeting, Nov 20, 2024

ResMed Elects Christopher DelOrefice to the Board

Chief Product Officer recently sold €9.5m worth of stock

Founder recently sold €4.6m worth of stock

Resmed Inc. Announces Board Changes

Chief Financial Officer recently sold €726k worth of stock

Recent updates

ResMed Inc., Annual General Meeting, Nov 20, 2024

ResMed Unveils New Collection of Digital and Personalized Solutions Designed to Improve Sleep Health

ResMed Elects Christopher DelOrefice to the Board

Chief Product Officer recently sold €9.5m worth of stock

Fourth quarter dividend of US$0.53 announced

Full year 2024 earnings released: EPS: US$6.94 (vs US$6.12 in FY 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 19, 2024

ResMed Inc. to Report Q4, 2024 Results on Aug 01, 2024

Now 37% undervalued

Now 29% undervalued after recent price drop

Investor sentiment improves as stock rises 20%

Third quarter dividend of US$0.48 announced

ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 13, 2024

Third quarter 2024 earnings released: EPS: US$2.05 (vs US$1.58 in 3Q 2023)

ResMed Inc. to Report Q3, 2024 Results on Apr 25, 2024

New major risk - Share price stability

ResMed Inc. Announces the U.S. Launch of the AirFit F40

New minor risk - Insider selling

Founder recently sold €4.6m worth of stock

Upcoming dividend of US$0.48 per share at 1.0% yield

Second quarter dividend of US$0.48 announced

New major risk - Share price stability

Second quarter 2024 earnings released: EPS: US$1.42 (vs US$1.53 in 2Q 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024

ResMed Secures Significant Victory in Patent Fight Against New York University

ResMed Secures Significant Victory in Patent Fight Against New York University

Resmed Inc. Announces Board Changes

Upcoming dividend of US$0.48 per share at 1.4% yield

Resmed Inc. Announces Declared Quarterly Cash Dividend, Payable on December 14, 2023

First quarter 2024 earnings released: EPS: US$1.49 (vs US$1.44 in 1Q 2023)

ResMed Inc. to Report Q1, 2024 Results on Oct 26, 2023

Investor sentiment deteriorates as stock falls 19%

Upcoming dividend of US$0.48 per share at 1.1% yield

New minor risk - Share price stability

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 21, 2023

Full year 2023 earnings released: EPS: US$6.12 (vs US$5.34 in FY 2022)

ResMed Inc. to Report Q4, 2023 Results on Aug 03, 2023

Chief Financial Officer recently sold €726k worth of stock

ResMed Inc. Announces Executive Changes

ResMed Inc. Announces Executive Changes

Upcoming dividend of US$0.44 per share at 0.7% yield

Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.22 in 3Q 2022)

Independent Director recently sold €123k worth of stock

Upcoming dividend of US$0.44 per share at 0.8% yield

Second quarter 2023 earnings released: EPS: US$1.53 (vs US$1.38 in 2Q 2022)

ResMed Inc. Declares Quarterly Dividend, Payable on March 16, 2023

ResMed Inc. to Report Q2, 2023 Results on Jan 26, 2023

Resmed Inc. Appoints Sandeep Gulati as General Manager, South Asia

Chief Financial Officer recently sold €848k worth of stock

Chief Financial Officer recently sold €848k worth of stock

Founder & Non-Executive Chairman recently sold €2.0m worth of stock

Upcoming dividend of US$0.44 per share

First quarter 2023 earnings released: EPS: US$1.44 (vs US$1.40 in 1Q 2022)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on December 15, 2022

ResMed Inc. to Report Q1, 2023 Results on Oct 27, 2022

ResMed Inc., Annual General Meeting, Nov 16, 2022

Now 20% undervalued

Now 21% undervalued

Full year 2022 earnings released: EPS: US$5.34 (vs US$3.27 in FY 2021)

ResMed Inc. Announces Cash Dividend for the Quarter of Fiscal Year 2022, Payable on September 22, 2022

ResMed Inc. (NYSE:RMD) acquired mementor DE GmbH.

ResMed Inc. to Report Q4, 2022 Results on Aug 11, 2022

ResMed Announces the Promotion of Lucile Blaise to President of Sleep & Respiratory Care, Effective July 1, 2022

ResMed Inc. (NYSE:RMD) agreed to acquire Medifox-Dan Dresden Gmbh for €950 million.

ResMed Inc. Announces Management Changes

Upcoming dividend of US$0.42 per share

Third quarter 2022 earnings released: EPS: US$1.22 (vs US$0.54 loss in 3Q 2021)

ResMed Inc. to Report Q3, 2022 Results on Apr 28, 2022

ResMed Announces Executive Changes